Skip to main content
. 2019 Sep 4;2019(9):CD005049. doi: 10.1002/14651858.CD005049.pub5

Naccarelli 1996.

Methods RCT
Open‐label
Loss to follow‐up reported: yes
Participants Any documented symptomatic AF. Type: paroxysmal 74%, persistent 26% (mean duration: 36 months). n = 239
Men: 38
Age (mean): 58 years
Structural heart disease: 83%. LAD: NS. LVEF: NS
Interventions Flecainide 200–300 mg/day vs quinidine 1–1.5 g/day
Method of AF cardioversion: pharmacological
Warfarin discretionary
Outcomes At 12 months:
Mortality
Proarrhythmia
Adverse effects
AF recurrence
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Method of randomisation not described.
Allocation concealment (selection bias) Unclear risk Procedure to conceal allocations not described.
Blinding (performance bias and detection bias) 
 All outcomes High risk Open‐label study.
Incomplete outcome data (attrition bias) 
 All outcomes Low risk All withdrawals and dropouts were well described.
Selective reporting (reporting bias) Low risk All prespecified and expected outcomes of interest were well reported.
Other bias Low risk No other bias apparent.